Parametrica Management’s Medicines Co MDCO Stock Holding History

Parametrica Management’s Portfolio MDCO Stock Details MDCO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-7,063	Closed	-$268K	–	463
2017 Q2	$268K	Buy	+7,063	New	+$315K	0.25%	157

Other funds holding MDCO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Corvex Management New York $2.52B AUM 25.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Parametrica Management's MDCO Position: Q3 2017 in Review

Parametrica Management sold out of Medicines Co (MDCO) in Q3 2017, closing a stake of 7,063 shares — an estimated $268K sold.

Parametrica Management first reported a position in MDCO in Q2 2017 and held it in 1 quarter. The position peaked at $268K in Q2 2017. 190 funds tracked by Wall St. Rank hold MDCO as of Q3 2017.

Parametrica Management reported no remaining Medicines Co position as of Q3 2017 after selling out during the quarter.
Parametrica Management sold 7,063 Medicines Co shares in Q3 2017, an estimated $268K.
Parametrica Management first reported a position in Medicines Co in Q2 2017 and held it in 1 quarter.
Parametrica Management's Medicines Co position peaked at $268K in Q2 2017.
190 funds tracked by Wall St. Rank held Medicines Co as of Q3 2017.

Based on Parametrica Management's 13F filing for Q3 2017, filed 27 Oct 2017.